CAS: 877397-65-4; (S)-1-(2,6-Dichloro-3-Fluorophenyl)Ethanol

上下游产品

CAS号877397-68-7 (1S)-1-(2,6-dic... | CAS号756520-66-8 1-(2,6-二氯-3-氟苯基)乙醇 | CAS号877397-67-6 1-(2,6-dichloro... | CAS号330156-50-8 (R)-1-(2,6-二氯-3... | CAS号877399-98-9 (R)-1-(2,6-dich... | CAS号877397-70-1 (R)-3-(1-(2,6-二...

(R)-1-(2,6-二氯-3-氟苯基)乙醇置于吡啶,Sodium Methylate体系中,用 甲醇,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 19.0H,反应生成 (S)-1-(2,6-二氯-3-氟苯基)乙醇
参考文献: Crizotinib For Use In The Treatment Of Cancer[fr] Crizotinib Pour L'Utlisation Dans Le Traitement De Cancer
标题: Crizotinib For Use In The Treatment Of Cancer[fr] Crizotinib Pour L'Utlisation Dans Le Traitement De Cancer
摘要:本发明涉及使用ros激酶抑制剂治疗哺乳动物体内异常细胞生长.具体而言,该发明提供了治疗患有癌症的哺乳动物的方法,其中至少有一个基因改变的ros介导.具体而言,该发明提供了通过给予克唑替尼治疗患有癌症的哺乳动物的方法,其中至少有一个基因改变的ros介导.

专利信息

专利号:US-7465842-B2
优先权日:2004-08-26
标 题 :Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates
发明人：KUNG PEI-PEI; MARTINEZ CARLOS; TAO JUNHUA
权利人:AGOURON PHARMA
摘要:The invention relates to biocatalytic methods for preparing enantiomerically pure stereoisomers of 1-(2,6-dichloro-3-fluorophenyl)ethanol. Disclosed are methods of preparation of the desired (S)-enantiomer, which methods are based on a combination of enzymatic resolution, chemical esterification and chemical hydrolysis with inversion of 1-(2,6-dichloro-3-fluorophenyl)ethyl esters or stereoselective bio-reduction of 2,6-dichloro-3-fluoro-acetophenone with a biocatalyst such as an enzyme or a microorganism. The chiral (S)-enantiomer can be used in the synthesis of certain enantiomerically enriched, ether linked 2-aminopyridine compounds that potently inhibit auto-phosphorylation of human heptocyte growth factor receptor.

专利号:CN-108285908-B
优先权日:2017-12-26
标题 :A kind of method for immobilized double enzyme catalyzed synthesis of (S)-1-(2,6-dichloro-3-fluoro-phenyl)ethanol

专利号:CN-119662581-A
优先权日:2025-01-27
标题 :Carbonyl reductase BsCR mutant, engineered bacteria and application in the synthesis of crizotinib chiral intermediates

专利号:US-2013072495-A1
优先权日:2010-05-14
标 题 :Fused bicyclic kinase inhibitors
发明人：LI AN-HU; MULVIHILL MARK J; STEINIG ARNO G
权利人:LI AN-HU; MULVIHILL MARK J; STEINIG ARNO G; OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as but not limited to tumors driven at least in part by at least one of RON, MET, IR, IGF-1R, or ALK. This Abstract is not limiting of the invention.

专利号:US-8785632-B2
优先权日:2004-08-26
标 题:Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
发明人：CUI JINGRONG JEAN; FUNK LEE ANDREW; JIA LEI; KUNG PEI-PEI; MENG JERRY JIALUN; NAMBU MITCHELL DAVID; PAIRISH MASON ALAN; SHEN HONG; TRAN-DUBE MICHELLE
权利人:CUI JINGRONG JEAN; FUNK LEE ANDREW; JIA LEI; KUNG PEI-PEI; MENG JERRY JIALUN; NAMBU MITCHELL DAVID; PAIRISH MASON ALAN; SHEN HONG; TRAN-DUBE MICHELLE; AGOURON PHARMA; PFIZER
摘要:Enantiomerically pure compound of formula 1 n nare provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

专利号:US-2012329826-A1
优先权日:2010-03-03
标 题:Substituted-5-aminopyrrolo/pyrazolopyridines
发明人：LI AN-HU; GUPTA RAMESH C; MULVIHILL MARK J; RAI ANAND NARAIN; WANG JING
权利人:LI AN-HU; GUPTA RAMESH C; MULVIHILL MARK J; RAI ANAND NARAIN; WANG JING; OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by RON and/or MET.